Zyme Communications
@zymecommunications.bsky.social
Specialist communications for life sciences
Shift Bioscience released new research detailing an improved framework for evaluating benchmark metric calibration in virtual cell models, reinforcing the use of AI virtual cells to accelerate target identification pipelines.
Learn more: shiftbioscience.com/shift-biosci...
Learn more: shiftbioscience.com/shift-biosci...
November 11, 2025 at 10:01 AM
Shift Bioscience released new research detailing an improved framework for evaluating benchmark metric calibration in virtual cell models, reinforcing the use of AI virtual cells to accelerate target identification pipelines.
Learn more: shiftbioscience.com/shift-biosci...
Learn more: shiftbioscience.com/shift-biosci...
Today @trimtechtx.bsky.social announced the appointment of Dr Mike Hutton to its Scientific Advisory Board.
Read the full press release here: trimtechtherapeutics.com/trimtech-the...
Read the full press release here: trimtechtherapeutics.com/trimtech-the...
November 11, 2025 at 9:36 AM
Today @trimtechtx.bsky.social announced the appointment of Dr Mike Hutton to its Scientific Advisory Board.
Read the full press release here: trimtechtherapeutics.com/trimtech-the...
Read the full press release here: trimtechtherapeutics.com/trimtech-the...
@sptlabtech.bsky.social and @alitheagenomics.bsky.social have collaborated to provide an automated solution for single-cell transcriptomics, integrating the MERCURIUS FLASH-seq with SPT’s firefly platform for high-throughput, cost efficient single-cell sequencing: www.sptlabtech.com/news/spt-lab...
November 5, 2025 at 9:18 AM
@sptlabtech.bsky.social and @alitheagenomics.bsky.social have collaborated to provide an automated solution for single-cell transcriptomics, integrating the MERCURIUS FLASH-seq with SPT’s firefly platform for high-throughput, cost efficient single-cell sequencing: www.sptlabtech.com/news/spt-lab...
Today Optibrium introduced the latest release of its comprehensive molecular design platform, StarDrop 8, integrating collaboration at every stage of the discovery process enabling medicinal chemists to progress more quickly from hit to candidate.
Read more here: bit.ly/4nGfpn9
Read more here: bit.ly/4nGfpn9
November 4, 2025 at 10:38 AM
Today Optibrium introduced the latest release of its comprehensive molecular design platform, StarDrop 8, integrating collaboration at every stage of the discovery process enabling medicinal chemists to progress more quickly from hit to candidate.
Read more here: bit.ly/4nGfpn9
Read more here: bit.ly/4nGfpn9
Today Nuclera announced expanded access to its eProtein Discovery System for APAC customers through a distributor agreement with Solve Scientific in Australia and New Zealand, providing localised support and expertise to scientists in these regions.
bit.ly/3LsJYz3
bit.ly/3LsJYz3
November 3, 2025 at 12:37 PM
Today Nuclera announced expanded access to its eProtein Discovery System for APAC customers through a distributor agreement with Solve Scientific in Australia and New Zealand, providing localised support and expertise to scientists in these regions.
bit.ly/3LsJYz3
bit.ly/3LsJYz3
@proimmune.bsky.social has introduced ProVE SL Self-Loading Class I Monomers, designed to offer unprecedented flexibility, speed and MHC allele-coverage in T cell research, with over 50 alleles available.
Read more: www.proimmune.com/news
Read more: www.proimmune.com/news
October 30, 2025 at 4:12 PM
@proimmune.bsky.social has introduced ProVE SL Self-Loading Class I Monomers, designed to offer unprecedented flexibility, speed and MHC allele-coverage in T cell research, with over 50 alleles available.
Read more: www.proimmune.com/news
Read more: www.proimmune.com/news
VALANX Biotech has appointed Klaus Orlinger, PhD. as CSO.
Klaus is an experienced R&D leader with a distinguished track record in pharmaceutical product development joining VALANX from HOOKIPA Pharma, where he served as CSO, VP Research, and Head of Virology.
Read more here: rb.gy/qva8kz
Klaus is an experienced R&D leader with a distinguished track record in pharmaceutical product development joining VALANX from HOOKIPA Pharma, where he served as CSO, VP Research, and Head of Virology.
Read more here: rb.gy/qva8kz
October 30, 2025 at 9:55 AM
VALANX Biotech has appointed Klaus Orlinger, PhD. as CSO.
Klaus is an experienced R&D leader with a distinguished track record in pharmaceutical product development joining VALANX from HOOKIPA Pharma, where he served as CSO, VP Research, and Head of Virology.
Read more here: rb.gy/qva8kz
Klaus is an experienced R&D leader with a distinguished track record in pharmaceutical product development joining VALANX from HOOKIPA Pharma, where he served as CSO, VP Research, and Head of Virology.
Read more here: rb.gy/qva8kz
Today Qureight announced that its Vascul8™ model for pulmonary vascular disorders has been validated in a peer reviewed study, offering the potential to improve treatment options and patient outcomes following surgery.
Read the full press release here: bit.ly/48OeEo5
Read the full press release here: bit.ly/48OeEo5
October 27, 2025 at 9:29 AM
Today Qureight announced that its Vascul8™ model for pulmonary vascular disorders has been validated in a peer reviewed study, offering the potential to improve treatment options and patient outcomes following surgery.
Read the full press release here: bit.ly/48OeEo5
Read the full press release here: bit.ly/48OeEo5
OMED Health, part of @owlstonemedical.bsky.social, has partnered with Aviva to deliver a pilot study, providing 75 Aviva employees with OMED Health Plans.
The collaboration will evaluate the impact of the OMED solution on the digestive health of participants: www.owlstonemedical.com/about/news/2...
The collaboration will evaluate the impact of the OMED solution on the digestive health of participants: www.owlstonemedical.com/about/news/2...
October 23, 2025 at 8:26 AM
OMED Health, part of @owlstonemedical.bsky.social, has partnered with Aviva to deliver a pilot study, providing 75 Aviva employees with OMED Health Plans.
The collaboration will evaluate the impact of the OMED solution on the digestive health of participants: www.owlstonemedical.com/about/news/2...
The collaboration will evaluate the impact of the OMED solution on the digestive health of participants: www.owlstonemedical.com/about/news/2...
Biodesix has expanded its partnership agreement with @biorad24.bsky.social to develop in vitro diagnostic assays for highly sensitive detection of genomic markers focused on oncology applications, utilizing Bio-Rad’s ddPCR™ technology & QX600 platform.
More here: rb.gy/5wbz3q
More here: rb.gy/5wbz3q
October 22, 2025 at 12:17 PM
Biodesix has expanded its partnership agreement with @biorad24.bsky.social to develop in vitro diagnostic assays for highly sensitive detection of genomic markers focused on oncology applications, utilizing Bio-Rad’s ddPCR™ technology & QX600 platform.
More here: rb.gy/5wbz3q
More here: rb.gy/5wbz3q
@proimmune.bsky.social has expanded into new global headquarters at Oasis Park, Oxford, supporting the continued development of ProImmune’s REVEAL Immunogenicity System and Ankyron target binding technologies.
Read more: proimmune.com/news
Read more: proimmune.com/news
October 22, 2025 at 8:11 AM
@proimmune.bsky.social has expanded into new global headquarters at Oasis Park, Oxford, supporting the continued development of ProImmune’s REVEAL Immunogenicity System and Ankyron target binding technologies.
Read more: proimmune.com/news
Read more: proimmune.com/news
giles AI has introduced giles, its specialised research agent designed to support healthcare, clinical, and medical research by optimising research intelligence for scientific text comprehension, enabling extraction and summarisation of academic papers: giles.app/press-releas...
October 22, 2025 at 8:02 AM
giles AI has introduced giles, its specialised research agent designed to support healthcare, clinical, and medical research by optimising research intelligence for scientific text comprehension, enabling extraction and summarisation of academic papers: giles.app/press-releas...
Bio-Rad Laboratories today announced that MicroVal, the international certification organization, has approved the iQ-Check Enterobacteriaceae Kit for real time detection of Enterobacteriaceae in infant formula, infant cereal, and related ingredients: www.bio-rad.com/en-uk/life-s...
October 21, 2025 at 9:09 AM
Bio-Rad Laboratories today announced that MicroVal, the international certification organization, has approved the iQ-Check Enterobacteriaceae Kit for real time detection of Enterobacteriaceae in infant formula, infant cereal, and related ingredients: www.bio-rad.com/en-uk/life-s...
Today Enamine announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of ASAP-0017445, a promising broad-spectrum coronavirus antiviral pre-clinical candidate.
Read more: enamine.net/news-press-r...
Read more: enamine.net/news-press-r...
October 21, 2025 at 8:13 AM
Today Enamine announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of ASAP-0017445, a promising broad-spectrum coronavirus antiviral pre-clinical candidate.
Read more: enamine.net/news-press-r...
Read more: enamine.net/news-press-r...
.@MosaicTXLtd has appointed Thomas Fuchs as CEO.
With over 25 years of experience across drug development and commercialisation, Thomas will lead the Company to advance its pipeline of proprietary drug combination programmes into the clinic: mosaic-tx.com/wp-content/u...
With over 25 years of experience across drug development and commercialisation, Thomas will lead the Company to advance its pipeline of proprietary drug combination programmes into the clinic: mosaic-tx.com/wp-content/u...
October 20, 2025 at 10:26 AM
.@MosaicTXLtd has appointed Thomas Fuchs as CEO.
With over 25 years of experience across drug development and commercialisation, Thomas will lead the Company to advance its pipeline of proprietary drug combination programmes into the clinic: mosaic-tx.com/wp-content/u...
With over 25 years of experience across drug development and commercialisation, Thomas will lead the Company to advance its pipeline of proprietary drug combination programmes into the clinic: mosaic-tx.com/wp-content/u...
Cyclana Bio today announced the close of a £5M pre-seed funding round that will enable the Company to develop functional disease models and its platform, for the identification of druggable targets in endometriosis.
More here: www.cyclanabio.com/general-8
More here: www.cyclanabio.com/general-8
October 20, 2025 at 10:06 AM
Cyclana Bio today announced the close of a £5M pre-seed funding round that will enable the Company to develop functional disease models and its platform, for the identification of druggable targets in endometriosis.
More here: www.cyclanabio.com/general-8
More here: www.cyclanabio.com/general-8
@sptlabtech.bsky.social and @10xgenomics.bsky.social have partnered to provide automated workflows for single cell research, scaling experiments on 10x’s Chromium Single Cell platform using plug-and-play protocols on SPT Labtech’s firefly platform: www.sptlabtech.com/news/spt-lab...
October 14, 2025 at 2:19 PM
@sptlabtech.bsky.social and @10xgenomics.bsky.social have partnered to provide automated workflows for single cell research, scaling experiments on 10x’s Chromium Single Cell platform using plug-and-play protocols on SPT Labtech’s firefly platform: www.sptlabtech.com/news/spt-lab...
This morning, CN Bio announced the launch of its all-in-one Organ-on-a-chip system, PhysioMimix Core.
The system combines the capabilities of CN Bio’s existing suite of instruments, enabling single-, multi-organ and higher-throughput configurations within one scalable platform.
bit.ly/3W6HxEv
The system combines the capabilities of CN Bio’s existing suite of instruments, enabling single-, multi-organ and higher-throughput configurations within one scalable platform.
bit.ly/3W6HxEv
October 14, 2025 at 8:26 AM
This morning, CN Bio announced the launch of its all-in-one Organ-on-a-chip system, PhysioMimix Core.
The system combines the capabilities of CN Bio’s existing suite of instruments, enabling single-, multi-organ and higher-throughput configurations within one scalable platform.
bit.ly/3W6HxEv
The system combines the capabilities of CN Bio’s existing suite of instruments, enabling single-, multi-organ and higher-throughput configurations within one scalable platform.
bit.ly/3W6HxEv
@sptlabtech.bsky.social and Agilent Technologies have introduced automated targeted enrichment protocols for genomic workflows. The protocols on SPT Labtech’s firefly+ platform use Agilent’s SureSelect Max DNA Library Prep Kits to increase reproducibility and reduce costs: tinyurl.com/5fmtwuf5
October 8, 2025 at 8:51 AM
@sptlabtech.bsky.social and Agilent Technologies have introduced automated targeted enrichment protocols for genomic workflows. The protocols on SPT Labtech’s firefly+ platform use Agilent’s SureSelect Max DNA Library Prep Kits to increase reproducibility and reduce costs: tinyurl.com/5fmtwuf5
FairJourney Biologics today announced the appointment of Dr. Werner Lanthaler as CEO, who previously served as Evotec SE CEO for 15 years.
Founder António Parada will focus on driving the Company's innovation strategy on the Supervisory Board.
Read more here: rb.gy/c31dis
Founder António Parada will focus on driving the Company's innovation strategy on the Supervisory Board.
Read more here: rb.gy/c31dis
October 8, 2025 at 8:25 AM
FairJourney Biologics today announced the appointment of Dr. Werner Lanthaler as CEO, who previously served as Evotec SE CEO for 15 years.
Founder António Parada will focus on driving the Company's innovation strategy on the Supervisory Board.
Read more here: rb.gy/c31dis
Founder António Parada will focus on driving the Company's innovation strategy on the Supervisory Board.
Read more here: rb.gy/c31dis
Owlstone Medical has won an award of up to $49.1 million from the Advanced Research Projects Agency for Health (ARPA-H) for the POSEIDON program, which aims to develop synthetic-sensor based Multi Cancer-Early Detection (MCED) at-home breath and urine tests: www.owlstonemedical.com/about/news/2...
October 6, 2025 at 9:34 AM
Owlstone Medical has won an award of up to $49.1 million from the Advanced Research Projects Agency for Health (ARPA-H) for the POSEIDON program, which aims to develop synthetic-sensor based Multi Cancer-Early Detection (MCED) at-home breath and urine tests: www.owlstonemedical.com/about/news/2...
@bio-rad.bsky.social has announced a strategic agreement with Gencurix that will establish Bio-Rad as the exclusive distributor of Gencurix’ CE-IVD Droplex™ digital PCR oncology testing kits throughout Europe.
More here: rb.gy/67rc7e
More here: rb.gy/67rc7e
October 2, 2025 at 8:34 AM
@bio-rad.bsky.social has announced a strategic agreement with Gencurix that will establish Bio-Rad as the exclusive distributor of Gencurix’ CE-IVD Droplex™ digital PCR oncology testing kits throughout Europe.
More here: rb.gy/67rc7e
More here: rb.gy/67rc7e
Tagomics published a peer-reviewed study in Cell Reports Methods, underpinning its epigenomic profiling technology, Active-Seq, the basis of Tagomics’ ActivaceTM platform
➡️ bit.ly/4nmE2FU
➡️ bit.ly/4nmE2FU
September 30, 2025 at 3:33 PM
Tagomics published a peer-reviewed study in Cell Reports Methods, underpinning its epigenomic profiling technology, Active-Seq, the basis of Tagomics’ ActivaceTM platform
➡️ bit.ly/4nmE2FU
➡️ bit.ly/4nmE2FU
Miebach Consulting has expanded its facilities at Abingdon Science Park, doubling its footprint with a new bespoke space in The Science Quadrant.
Delivered by Kadans Science Partner, the new facilities offer flexible workspaces to support future growth: www.kadans.com/news/miebach...
Delivered by Kadans Science Partner, the new facilities offer flexible workspaces to support future growth: www.kadans.com/news/miebach...
September 25, 2025 at 12:49 PM
Miebach Consulting has expanded its facilities at Abingdon Science Park, doubling its footprint with a new bespoke space in The Science Quadrant.
Delivered by Kadans Science Partner, the new facilities offer flexible workspaces to support future growth: www.kadans.com/news/miebach...
Delivered by Kadans Science Partner, the new facilities offer flexible workspaces to support future growth: www.kadans.com/news/miebach...
Today SynGenSys announced the launch of NK.SET™, the first commercially available NK (natural killer) cell-specific promoter library enabling precise and controllable gene expression.
Read the full press release here: www.syngensys.com/resources/nk
Read the full press release here: www.syngensys.com/resources/nk
September 23, 2025 at 8:59 AM
Today SynGenSys announced the launch of NK.SET™, the first commercially available NK (natural killer) cell-specific promoter library enabling precise and controllable gene expression.
Read the full press release here: www.syngensys.com/resources/nk
Read the full press release here: www.syngensys.com/resources/nk